Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid TumorsJoachim Drevs, Clemens Unger, Jane Robertson et al.|Journal of Clinical Oncology|2007Cited by 303
Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid TumorsMarlies H.G. Langenberg, Emile E. Voest, Carla M.L. van Herpen et al.|Journal of Clinical Oncology|2009Cited by 95
Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studiesC. van Herpen, Giuseppe Giaccone, Joachim Drevs et al.|Journal of Clinical Oncology|2007Cited by 10
Cediranib targeting of circulating VEGFR-1+ monocyte subpopulationsHua Wu, John V. Heymach, Amado J. Zurita et al.|Journal of Clinical Oncology|2008Cited by 1